Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy

Bladder Cancer Clinical Trial

Official title:

Randomized Clinical Trial of Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03469362
• Other study ID #: 20170004
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 25, 2018
• Est. completion date: April 30, 2026

Study information

• Verified date: May 2024
• Source: University of Miami
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intracorporeal urinary diversion (ICD) provides superior postoperative outcomes compared to extracorporeal urinary diversion (ECD). The investigators' hypothesis that ICD may provide clinical benefit is based on principles of less bowel and ureteral handling, superior operating room workflow, less exposure to the external environment, and optimal visualization with ICD while utilizing a smaller incision compared to ECD. ICD should have less bowel-related complications, lower pain scores allowing patients to be discharged from the hospital sooner and regain functional independence more quickly.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 38
• Est. completion date: April 30, 2026
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Biopsy-proven urothelial cancer being considered for RARC.

• Clinical stage T1-T4, N0-1, M0 or refractory carcinoma in situ.

• Subject must be already scheduled to have a RARC at the discretion of the surgeon and with the patient's agreement.

Exclusion Criteria:

• Inability to give informed consent

• Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.

• At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.

• Age <18 or >99 years.

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Procedure:
• Extracorporeal Urinary Diversion
Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
• Intracorporal Urinary Diversion
Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.

Device:
• Da Vinci Robot
Da Vinci Robotic Surgical System

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	90-day Major Post-Operative Complication Rate	Major complication rate at 90-days from RARC + urinary diversion using the modified Clavien-Dindo grading system. Major complication is defined as Clavien-Dindo Grade = 3.	90 days
Secondary	90-day Any Post-Operative Complication Rate	Any complication rates at 90-days from RARC + urinary diversion, using the modified Clavien-Dindo grading system as low grade (1-2) or high grade (3-5).	90 days
Secondary	Length of Hospital Stay in ECD vs ICD Study Participants	Length of hospital stay for study participants undergoing ECD versus ICD urinary diversion post-RARC, as recorded at hospital discharge.	About 2 weeks
Secondary	90-day Readmission Rate	Rate of readmission to hospital at 90 days post-RARC followed by ECD or ICD urinary diversion.	90 days
Secondary	Rate of Return to the Operating room within 90 days	Rate of return to the operating room within 90 days after RARC followed by ICD or ECD Urinary Diversion.	Up to 90 days
Secondary	Mortality Rate at 90 days	Rate of mortality (death) at 90 days in study participants	90 days
Secondary	Rate of Bowel-Specific Complications	Rate of bowel-specific complications in study participants (including incidence of mechanical bowel obstruction, anastomotic leaks, and surgical site infections) and post operative pain. Bowel-specific complications will be assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.	Up to 36 months
Secondary	Functional Independence Recovery as measured by the ADL Questionnaire	Rate of functional independence recovery as measured by patient-reported scores on the Activities of Daily Living (ADL) questionnaire. For the ADL, the total score ranges from 0 to 6, with the higher scores indicating functional improvement and lower scores indicating functional deterioration.	Up to 36 months
Secondary	Functional Independence Recovery as measured by the IADL Questionnaire	Rate of functional independence recovery as measured by an aggregate of patient-reported scores on the Instrumental Activities of Daily Living (IADL) questionnaire. For the IADL, the total score ranges from 0 to 8, with higher scores indicating functional functional improvement and lower scores indicating functional deterioration.	Up to 36 months
Secondary	Functional Independence Recovery as measured by the Hand Grip Strength Test.	The Hand Grip Strength Test measures the amount of static force that a participant's hand can squeeze around a dynamometer. The test is measured in kilograms.	Up to 36 months
Secondary	Functional Independence Recovery as measured by the Timed Up and Go (TUG) Walking Test	The TUG test times participants as they rise from a standard chair, walk 3 meters, turn, walk back and sit again. The test is measured in seconds.	Up to 36 months
Secondary	Health-Related Quality of Life (HRQoL) as assessed by SF-8 Health Survey	HRQoL measured by patient scores on the Short Form 8 (SF-8) Health Survey. The SF-8 is a questionnaire consisting of 8-items and two component summary scores: Physical component summary (PCS) and mental component summary (MCS). They are scored by weighting each score to a norm-based scoring model. The total scores will be reported as a percentile with higher score indicating better health-related quality of life.	Up to 36 months
Secondary	HRQoL as assessed by the FACT-VCI Questionnaire	HRQoL measured by patient scores on the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) questionnaire. The FACT-VCI is a condition-specific instrument for patients undergoing radical cystectomy (RC) and urinary diversion (UD) for bladder cancer. The questionnaire consists of 44 items scored on a range from 0 ("Not at all") to 4 ("Very Much"), resulting in an ordinal Likert scale, with higher scores indicating a better HRQoL. The FACT-VCI measures quality of life across five domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and an additional concerns subscale.	Up to 36 months